The ELuminexx vascular stent is a flexible, self-expanding nitinol stent to be marketed by the Bard peripheral vascular division, located in Tempe, Arizona. The device is intended to treat patients with common or external iliac artery occlusive disease.
Previously, Bard’s prospective, multi-center, non-randomized, clinical study of 134 patients measuring the ELuminexx vascular stent against objective performance criteria demonstrated a nine-month primary patency of 94.03% and a site reported anatomic success rate (<30% final residual stenosis) of 98.72%. Timothy Ring, chairman and CEO of Bard, said: "The ELuminexx vascular stent joins the recently approved Flair endovascular stent graft to position Bard as the only medical device company offering both a stent and a stent graft with peripheral vascular indications in the US. "The anticipated approval of the LifeStent FlexStar Stent for the treatment of superficial femoral artery disease will further enhance our comprehensive offerings to address challenges associated with the treatment of peripheral vascular disease."